Cargando…

The potential benefit of endothelin receptor antagonists’ therapy in idiopathic pulmonary fibrosis: A meta-analysis of results from randomized controlled trials

Fibrotic diseases take a very heavy toll in terms of morbidity and mortality equal to or even greater than that caused by metastatic cancer. This meta-analysis aimed to evaluate the effect of endothelin receptor antagonists on idiopathic pulmonary fibrosis. METHOD: A systematic search of the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuang, Pan, Yong-li, Xin, Wenqiang, Yan, Chunhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543018/ https://www.ncbi.nlm.nih.gov/pubmed/36221345 http://dx.doi.org/10.1097/MD.0000000000029981

Ejemplares similares

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)

Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists
por: Nishimura, Masato, et al.
Publicado: (2016)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
por: Steiner, M Kathryn, et al.
Publicado: (2008)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials
por: Ma, Junpeng, et al.
Publicado: (2012)

The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
por: Gu, Zhi-Chun, et al.
Publicado: (2018)

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
por: Badagliacca, Roberto, et al.
Publicado: (2020)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review
por: Zhang, Li, et al.
Publicado: (2020)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
por: Zhang, Zeyu, et al.
Publicado: (2022)

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
por: Hamidi, Sayyed A, et al.
Publicado: (2011)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
por: Vainshelboim, Baruch
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review
por: Nahar, Shamsun, et al.
Publicado: (2023)

Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases
por: Pulito-Cueto, Verónica, et al.
Publicado: (2023)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist
por: Chang, Sung-A
Publicado: (2014)

Clinical and hemodynamic effect of endothelin receptor antagonists in Eisenmenger Syndrome
por: Yonas, Emir, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer
por: Qi, Ping, et al.
Publicado: (2015)

Insights into Endothelin Receptors in Pulmonary Hypertension
por: Liu, Ruiqi, et al.
Publicado: (2023)

The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
por: Kuang, Hong-Yu, et al.
Publicado: (2018)

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
por: Verweij, Pierre, et al.
Publicado: (2020)

Distortion of K(B) estimates of endothelin‐1 ET(A) and ET(B) receptor antagonists in pulmonary arteries: Possible role of an endothelin‐1 clearance mechanism
por: Angus, James A., et al.
Publicado: (2017)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
por: Enevoldsen, Frederik C., et al.
Publicado: (2020)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
por: Cao, Fen, et al.
Publicado: (2023)

Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor
por: Montgomery, Jennifer P, et al.
Publicado: (2008)

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
por: Gatfield, John, et al.
Publicado: (2012)

Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012)

Treatment of nonarteritic anterior ischemic optic neuropathy with an endothelin antagonist: ENDOTHELION (ENDOTHELin antagonist receptor in Ischemic Optic Neuropathy)—a multicentre randomised controlled trial protocol
por: Chiquet, Christophe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8eg95brfcpsep77p8b8vk9csgg